We investigated the effect of obesity on the serum levels of total and free IGF-1 and their relationship to the circulating levels of insulin and IGF binding proteins (IGFBPs) in age and sex-matched groups. SUBJECTS: The study included 43 obese subjects (ideal body weight; IBW b 120%) and 45 controls (IBW`100%). All of the subjects were male. MEASUREMENT: Total IGF-1, free IGF-1, IGFBP-1, IGFBP-2, IGFBP-3, and insulin were measured in obese subjects and normal control subjects. RESULTS: No signi®cant differences in the circulating levels of total and IGFBP-3 were observed between the obese and control groups. In contrast to total IGF-1, free IGF-1 in obese subjects was signi®cantly increased compared to normal controls (P`0.05). Serum total and free IGF-1 were inversely correlated with age (r À0.42, P 0.001, and À0.44, P 0.001). Fasting serum insulin concentrations were elevated in all the obese subjects (P`0.05) and positively correlated with IBW (r 0.57, P 0.001). The levels of serum GH and IGFBP-1 were suppressed in all the obese subjects (P`0.05). IGFBP-1 was inversely correlated with IBW (r À0.51, P 0.001) and serum insulin concentrations (r À0.48, P 0.001). The IGFBP-2 concentrations were also suppressed in obese subjects and inversely related to free IGF-1 (r À0.48, P 0.001). Using multiple linear regression analysis, total IGF-1 and insulin concentrations were positively correlated (r 0.58, P 0.001) and free IGF-1 and IGFBP-1 concentrations were negatively correlated (r À0.57, P 0.001). CONCLUSION: We con®rmed that total IGF-1 and IGFBP-3 concentrations were not signi®cantly different between the obese and control groups, despite GH hyposecretion in obesity. We also found that free IGF-1 concentrations were higher in obese subjects than in normal controls. It seems likely that overnutrition and chronic hyperinsulinaemia in obesity may alter this regulated growth response by insulin stimulation of IGF-1 production and suppression of hepatic IGFBP-1 and IGFBP-2 production, which may inhibit IGF-1 bioactivity.
Introduction
Obesity is associated with the impairment of normal GH (growth hormone) secretion and blunted responses to all stimuli such as GH-releasing hormone (GHRH), hypoglycaemia, L-dopa, arginine, glucagon, physical exercise, and sleep. 1±4 Based on the well known GH hyposecretion in obesity,`GH-dependent' insulin-like growth factor (IGF)-1 concentrations would be expected to be subnormal in obesity. However, the results have been con¯icting, 5±7 due to clinical differences in age, sex and degree and type of obesity.
Circulating IGF-1 is predominantly bound in a ternary 150 kDa complex, consisting of IGF-1, IGFbinding protein (IGFBP)-3, and an acid-labile subunit. 8, 9 Thus IGFBP-3 and IGF-1 have relatively long half-lives in the circulation, 10 and since they are GH dependent they represent a stable index of long-term changes in GH availability and action. 11 IGFBP-2 is the second most abundant IGF-binding protein in serum. The serum concentration of IGFBP-2 is known to be inversely related to GH secretion, being high in states of GH de®ciency and low in states of GH excess. 12 These reports have suggested that measurement of IGFBP-2 might be useful in detecting GH de®ciency. In contrast, the serum concentrations of IGFBP-1 are lower than those of IGFBP-3 and IGFBP-2, and acutely regulated by food intake and¯uctuations in serum insulin and glucose concentrations. 13±15 Because of this unique property, IGFBP-1 is thought to play an important role in acute regulation of IGF-1 availability. 16, 17 In previous reports, IGFBP-1 sequestered free IGF-1 and inhibited its metabolic actions. 18, 19 A small portion of circulating IGF-1 is detected in the free or readily dissociable state, which is thought to be the metabolically active form. The amount of free/dissociable IGF-1 in serum is dependent on a complex interplay between the production rate and concentrations of IGF-1 and IGFBPs. 10 In this study, we investigated the effect of obesity on the serum concentrations of total and free IGF-1 and their relationship to the concentrations of IGFbinding proteins and insulin in age and sex-matched groups.
Subjects and methods

Subjects and protocol
Forty-three obese Korean males aged 20±49 y (mean -AE s.e.m., 34.9 AE 7.9) and 45 normal Korean male subjects aged 20±49 y (33.9 AE 8.3) were studied. The normal control subjects were within 10% of their ideal body weight (IBW), and the obese subjects weighed more than 120% of ideal body weight, as determined by the Fogarty Center Conference on Obesity. All subjects were recruited from subjects attending the medical-checkup programs at the health-care centre of Yong Dong Severance Hospital.
An oral glucose tolerance test was performed on each subject to screen out impaired glucose tolerance or diabetes mellitus. Apart from obesity, no abnormalities were detected. No subjects had used any hormonal preparations or drugs within the 60 d prior to the study.
The study was approved by the Hospital Ethics Committee, and informed consent was obtained from each subject.
Blood samples were obtained from each subject by venepuncture between 08:00 am and 10:00 am after an overnight fast. Serum was separated by centrifugation, and stored at À20 C until analysis.
Analytical methods
Serum glucose level was measured by the glucoseoxidase method and insulin level by enzyme-linked immunoadsorbent assay (ELISA). This ELISA uses two monoclonal antibodies (Novo Nordisk A/S, Denmark) directed against human insulin and does not cross-react with human proinsulin. Serum triglyceride and cholesterol concentrations were determined in the overnight fasting state with semi-automated methods (Boehringer, Mannheim, Germany). Serum GH was measured by an immunoradiometric assay (IRMA) from Daiichi (Tokyo, Japan); the sensitivity was 0.1 mg/L and its intra and interassay coef®cients of variations were 1.3 and 1.4%, respectively. Serum IGFBP-1, IGFBP-2, and IGFBP-3 were measured by an immunoradiometric assay (IRMA) kit (Diagnostic System Laboratories, Inc. Webster, TX); the sensitivities were 0.01 ng/mL, 0.5 ng/mL, 0.5 ng/mL, respectively and their intra and inter-assay coef®cients of variations were less than 10%. Serum total IGF-1 was measured by an IRMA kit (Diagnostic System Laboratories, Inc. Webster, TX); the sensitivity was 0.3 mg/L and its intra and interassay coef®cients of variations were less than 10%. Free/dissociable IGF-1 concentrations were measured by a highly sensitive two-site IRMA kit (Diagnostic System Laboratories, Inc. Webster, TX) according to the manufacturer's suggestions. Assay characteristics have been reported previously. 20 This is a direct detection assay in which 100 mL of serum sample are added to tubes containing a dense coating of high af®nity anti-IGF-1 antibody, which binds IGF-1 that is not bound to or is easily dissociable from IGFBPs. Samples were then incubated for two hours at 2±8 C, washed, and incubated with an 125 I-labeled anti-IGF-1 antibody directed to a second epitope of IGF-1 for two hours at room temperature. After decanting and washing 3 times, the tubes were counted in a g-counter. Assay standards were recombinant human (rh)IGFÀ1 (0.13±20 mg/L). The minimal detection limit was 0.05 mg/L or 5 pg/ tube. According to the manufacturer's speci®cations and previous characterization of the assay, there was no cross-reactivity with IGF-II, and no residual IGFBP-1 or IGFBP-3 was detectable in the assay tube after the ®rst wash. 20 The interassay coef®cients of variations were 7.7, 3.6 and 10.7% at 0.26, 5.52 and 13.87 ng/mL, and the intraassay coef®cients of variations were 10.3, 5.1, and 3.3% at 0.29, 6.26, and 14.20 ng/mL. All samples from each subject were analyzed in duplicate at the same time.
Statistical analysis
The results were expressed as the mean AE s.e.m. Statistical comparisons were made using the Student's unpaired t-Test between obese and control groups. Correlation between different parameters was calculated by linear regression analysis. Factors related to total and free IGF-1 were analyzed using stepwise multiple regression. P`0.05 was accepted as the signi®cance level.
Results
Percentage of ideal body weight (138.2 AE 11.7%, mean AE s.e.m.), BMI (30.0 AE 2.5 kg/m 2 ), and waist to hip ratio (0.93 AE 0.2) in obese subjects were signi®-cantly (P`0.001) higher than those of normal controls (97.6 AE 6.4%, 21.3 AE 1.4 kg/m 2 , and 0.84 AE 0.0). Fasting serum glucose (FSG), total cholesterol, triglyceride, insulin and GH concentrations are summarized in Table 1 .
The FSG, triglyceride and insulin concentrations in obese subjects were signi®cantly greater than those of normal controls. In all obese subjects, fasting GH concentrations were suppressed as compared with control subjects (P`0.05).
No signi®cant differences in the circulating concentrations of the total IGF-1 and IGFBP-3 were observed between the control and obese subjects (Figure 1 ). Serum total IGF-1 was weakly correlated with IGFBP-3 (r 0.28, P 0.05). The free IGF-1 concentrations were signi®cantly elevated in obese subjects (1.46 AE 1.1 mg/L vs 0.91 AE 0.9 mg/L, P`0.05; Figure 1 ). The ratio of free to total IGF-1 also was higher in obese subjects (0.63% vs 0.39%, P`0.05; Figure 1 ).
The IGFBP-1 concentrations were signi®cantly lower in the obese subjects ( Figure 1 ) and negatively correlated with percent of IBW (r À0.51, P 0.001) and serum insulin (r À0.48, P 0.001).
The IGFBP-2 concentrations were also suppressed in obese subjects (P`0.05; Figure 1 ) and inversely related to free IGF-1 (r À0.48, P 0.001). Additionally, the ratio of IGFBP-2 to IGF-1 was decreased (1.6 AE 0.5 vs 2.2 AE 1.4, P`0.005) in obese subjects.
Using multiple linear regression analysis, the total IGF-1 and free IGF-1 were analyzed by age, IBW, WHR, fasting serum insulin, GH, IGFBP-1, IGFBP-2, and IGFBP-3 in all subjects. Of all variables, age and serum insulin concentrations were associated with serum total IGF-1. The total IGF-1 was inversely correlated with age (r À0.42, P`0.001) and positively correlated with serum insulin (r 0.58, P`0.001). The free IGF-1 was negatively correlated with age (r À0.44, P`0.001) and IGFBP-1 (r À0.57, P`0.001).
Discussion
Using age and sex matched subjects, we con®rmed that GH levels were reduced in the obese while`GHdependent' total IGF-1 levels were not signi®cantly different between obese and control subjects. Similar results have been reported previously, 21±23 but the contradictory ®ndings of increased or decreased IGF-1 levels found by others, although due in part to important clinical differences in age, sex and degree of obesity in the different studies, could be profoundly in¯uenced by nutritional factors. 24, 25 In addition, the discordant relationship between GH and IGF-1 in obesity may be also explained by the hyperinsulinaemia present in obesity: 26 insulin may increase hepatic IGF-1 production. 27 We found a positive correlation between the serum total IGF-1 and insulin concentrations.
A small portion of circulating IGF-1 is detected in the free or readily dissociable state, which is thought to be the metabolically active form. 28, 29 In the present study, free/dissociable IGF-1 was assessed by a twosite immunoradiometric assay. The absolute values for free/dissociable IGF-1 in both obese and control groups were higher than those reported by Frystyk et al 30 using RIA after separation by centrifugal ultra®ltration. The difference between our results and theirs are mostly likely due to the ages of subjects; older subjects have lower total and free IGF-1. 30 However, the ratios of free to total IGF-1 in both groups are similar between the two assay systems.
The amount of free/dissociable IGF-1 in serum is dependent on a complex interplay between the production rate and the concentrations of IGF-1 and IGFBPs. IGFBP-3 serves as major stabilizer of the circulating IGF pool. Circulating IGFBP-3 might undergo limited proteolysis, which results in smaller molecular weight IGFBP-3 fragments that have lower af®nity for IGF-1 than the intact binding protein.
Consequently, the levels of free/dissociable IGF-1 are elevated in situations where IGFBP-3 proteolysis is increased. 31 Bereket et al 32 showed that acute mealrelated hyperinsulinaemia did not increase IGFBP-3 proteolysis. However, it is not known whether IGFBP-3 proteolysis increases in obese subjects.
In contrast, IGFBP-1 exhibits marked diurnal variation in relation to meals. 32 Insulin is the principal regulator of IGFBP-1 and is reported to inhibit hepatic IGFBP-1 synthesis. 33 Because of this property, IGFBP-1 is thought to play an important role in the regulation of IGF bioactivity. Therefore, the obesityrelated hyperinsulinaemia may decrease circulating concentrations of IGFBP-1, which can result in elevated free IGF-1 in obesity. In our study, circulating IGFBP-1 concentrations in obese subjects were lower than normal controls. There were also negative correlations between free IGF-1 and IGFBP-1.
IGFBP-2 is the second most abundant IGF-binding protein in serum. 34 Several reports have shown that IGFBP-2 is differentially regulated by GH and IGF-1.
12,34 Administration of GH causes a reduction in IGFBP-2, while the serum concentration of IGFBP-2 is high in states of GH de®ciency. 34 In normal adults, the infusion of IGF-1 results in suppression of GH and an increase in IGFBP-2. 38 The dissociation of the effect of GH and IGF-1 in regulating IGFBP-2 suggests that IGFBP-2 and the ratio of IGFBP-2 to IGF-1 may be useful in detecting GH de®ciency. Thus, based on the well-known GH hyposecretion in obesity, the levels of IGFBP-2 and the ratio of IGFBP-2 to IGF-1 would be expected to be high. However, we found that IGFBP-2 concentrations and the ratios of IGFBP-2 to IGF-1 were suppressed in obese subjects. These ®nd-ings indicate that factors other than GH may be regulating serum IGFBP-2 in obesity. Clemmons et al 34 showed that acute stimulation of insulin did not suppress IGFBP-2, but IGFBP-2 concentrations were elevated after prolonged fasting. This suggests that prolonged changes in insulin secretion may result in a signi®cant change of IGFBP-2. It appears, therefore, that the obesity-related chronic hyperinsulinaemia may result in suppression of IGFBP-2 in obesity. We also found a negative correlation between IGFBP-2 and free IGF-1 concentrations. This indicates that IGFBP-2 can quantitatively in¯uence IGF-1 transport and may have some role in regulating IGF-1 bioavailability in obesity, because serum IGFBP-2 are more abundant than IGFBP-1 in adults. 34 
Conclusions
We con®rmed that`GH-dependent' IGF-1 and IGFBP-3 concentrations were not signi®cantly different between obese and control groups, despite the GH hyposecretion in obesity. We also found that free IGF-1 concentrations were increased in obesity compared to normal controls. It seems likely that overnutrition and chronic hyperinsulinaemia in obesity may alter this regulated growth response: insulin may stimulate production of IGF-1 and suppress production of IGFBP-1 and IGFBP-2, which are thought to be inhibitory IGFBPs.
